Tuesday, 23 October 2018
Topics
Meeting category
Date(s)
23 Oct 2018
Location
The Hague,
Netherlands
Organizer
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Related Enduring Materials
Enduring Materials
- 08:30
08:30
Workshop Opening
Rob Aarnoutse, PharmD, PhD
Radboud University Medical Center, The Netherlands
Session 1: Pharmacokinetics and pharmacodynamics of new TB drugs -
Chairs
Rob Aarnoutse, PharmD, PhD
Radboud University Medical Center, The Netherlands
Jan-Willem Alfenaar
University of Groningen
08:45
New developments in pediatric TB treatment
Anneke Hesseling
Desmond Tutu Tuberculosis Centre, South Africa
Oral abstract presentations
09:45
CPK/PD Support for a Phase 1 Study of TBA-7371
09:45
Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect
10:00
Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline
10:15
TPreclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid
Session 2: Pharmacokinetics and pharmacodynamics of approved TB drugs -
Chairs
Geraint Davie, MD
University of Liverpool, UK
Helen McIlleron, MBChB, PhD
University of Cape Town, South Africa
Oral Abstract presentations
11:15
Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB
11:30
Rifampicin, isoniazid and pyrazinamide exposures in children with DS-TB on WHO-recommended FDCs in the SHINE trial
Helen McIlleron, MBChB, PhD
#6
11:45
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention
12:00
Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers
12:15
Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis
12:30
Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients
Session 3: Population pharmacokinetics and pharmacokinetic-pharmacodynamic modeling -
Chairs
Jerry Nedelman, PhD
TB Alliance
Eric Nuermberger, MD
Johns Hopkins University, USA
14:15
Treatment of Multi-Drug Resistant TB
Oral abstract presentations
15:00
High peak rifampicin concentrations accelerate the slow phase of bacterial elimination in tuberculosis patients
15:15
The Clinical value of Model-based Therapeutic Drug Monitoring in Tuberculosis Treatment – Optimized Target for Rifampicin
Robin J Svensson
#12
15:30
Model-based meta-analysis of rifampicin exposure and mortality in phase II tuberculosis meningitis trials
15:45
Pharmacokinetic-pharmacodynamic modeling of pretomanid in pulmonary tuberculosis patients
Michael Lyons, PhD
#14
Session 4: Drug development and optimization: approaches and tools -
Chairs
Kelly Dooley, MD, PhD
Johns Hopkins University, USA
Oral Abstract presentations
16:45
Clinical Validation of Intracellular Pharmacodynamic (PDi) based modelling for the prediction of Fluoroquinolone activity against TB
17:00
PK-PD arguments for bedaquiline and delamanid replacement of aminoglycosides in MDR-TB regimens
Jansy Sarathy, PhD
#16
17:15
Pharmacodynamic Correlates of Linezolid Activity and Toxicity in a Mouse TB Model
17:30
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis
17:45
Protein binding of rifampicin is not saturated when using high-dose rifampicin
18:00
Using Mycobacterium tuberculosis single nucleotide polymorphisms to predict fluoroquinolone treatment response
18:15
Closure and adjournment
Overview
Image
Welcome
The Organizing Committee for the 11th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs is pleased to share that the meeting was a grand success.
Make sure that you are subscribed to our newsletter to stay up to date on upcoming events.
Kind regards,
The Organizing Committee
General Information
Meeting Objectives
- To gather experts involved in the pharmacology of TB drugs from different disciplines in an interactive workshop setting
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB
Unique Features
Our workshop involves a strong community of clinical pharmacologists and other healthcare professionals working in the TB-field. Also, the workshop provides an independent scientific platform to discuss controversial topics and views.
Practical Information
Language
The official conference language was English. No simultaneous translation was provided.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Academic Medical Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Academic Medical Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Photograph, Audio and Video Recording
Photographs as well as audio and video recordings are not permitted during official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted on the workshop website as soon as possible following the meeting, provided the speaker has given us permission to use their presentation online.
